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Introduction
Biologic treatments have been introduced for Juvenile
Idiopathic Arthritis (JIA) treatment in 2000, and have
substantially improved the global prognosis of all disease
subtypes. However not all patients respond to one biologic
and therapeutic effect of one drug may decrease with time.
Objectives
We aimed to analyse, in current practice, the switch to
another biologic, and the drug survival for treatment
according to all JIA subtypes
Methods
Patients included in the juvenile inflammatory rheuma-
tism (JIR) cohort, including ten Swiss, French and Belgian
centers for pediatric rheumatology, were analyzed
retrospectively.
Results
529 JIA patients, sex ratio: 0.5 (175M/354F), aged between
1 to 22 years at the onset of biologic treatment (mean 10.4
sd 4.4) were analysed. Their diseases were as follows:
enthesitis-related arthritis (ERA: 19%), oligoarthritis
(Oligo: 28%), polyarthritis (Poly: 27%), psoriatic arthritis
(Pso: 5%), systemic-onset arthritis (SoJIA: 17%), and unde-
fined (4%). Anti-TNFs were the most frequent biologics
used as first line: Etanercept for 66.5% (less frequent for
So: 47%), adalimumab for 13.4% and infliximab for 10%.
The first biologic remained the only one in most cases
(66%). The reasons to stop these treatments were: lack of
efficacy for 12% (63), complete remission for 11% (57) and
side effect for 7%. The second line biologic the most used
was for SoJIA: anakinra (28%) and tocilizumab (24%)
whereas adalimumab was the most frequent for other JIA
subtypes. Tocilizumab was the top 3rd line for SoJIA
(32%), and abatacept for the other subtypes. The mean
drug survival in months at the date of inclusion was: 26
for etanercept, 23 for adalimumab, 12 for infliximab, 23
for anakinra, 22 for tocilizumab, 13 for abatacept but half
of patients (n=265) were still on treatment at inclusion in
the JIR cohort. The mean drug survival was not influenced
by JIA subtype. We found a significant difference in
patients having received more than two biotherapies,
between SoJIA and Poly (25%) compared to other JIA
subtypes (5%).
Conclusion
Etanercept was the first biologic treatment used whatever
the JIA subtype, in this retrospective study that includes
patients treated since more than 10 years. Two third of
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